The human papillomaviruses (HPVs) are associated with specific human cancers. Over 70 different HPVs have now been identified, of which, over 25 have been associated with genital tract lesions. HPVs can be further classified as either """"""""high risk"""""""" (HPV 16,18) or """"""""low risk"""""""" (HPV 6,11) based on the clinical lesions with which they are associated and the relative propensity for these lesions to progress to cancer. Approximately 85-90 percent of human cervical cancers harbor the DNA of a """"""""high risk"""""""" HPV type and express the two well characterized viral oncoproteins, E6 and E7. One characteristic of HPV related carcinogenic progression is the frequent integration of the viral genome into the human chromosome in the cancer cells. This integration occurs in a manner that results in the loss of expression of the viral E2 gene leading to high levels of E6/E7 expression. Several observations suggest that the loss of E2 expression may be an important step in HPV associated carcinogenic progression. First, the E2 regulatory protein encoded by the genital HPVs can repress the E6/E7 promoter. Second, HPV16 genomes with mutations in the E2 open reading frame have an increased immortalization capacity in primary keratinocytes. Finally, the reintroduction of the E2 gene into HPV positive cervical carcinoma cell lines leads to suppression of growth and cell cycle arrest. The current model for the role of E2 in this process involves the down regulation of the E6/E7 promoter, resulting in the loss of expression of the viral oncoproteins, the induction of p53 and p21, and the consequent inhibition of the cyclin dependent kinases, leading ultimately to a G1 cell cycle arrest. However, recent data suggest that E2 transcriptional repression of E6/E7 is necessary but not sufficient to cause cellular growth suppression. Comparison of the activities of various BPV1 E2 proteins to those of the oncogenic and """"""""low risk"""""""" HPV E2 proteins indicates that E2 mediated growth arrest involves an additional activity that is independent of E2s ability to repress transcription of the viral E6/E7 promoter. In this grant application, we propose to examine the mechanisms by which E2 causes cellular growth suppression.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA077385-05S1
Application #
6573096
Study Section
Virology Study Section (VR)
Program Officer
Rosenfeld, Bobby
Project Start
1998-05-01
Project End
2003-01-14
Budget Start
2002-03-01
Budget End
2003-01-14
Support Year
5
Fiscal Year
2002
Total Cost
$76,975
Indirect Cost
Name
Harvard University
Department
Pathology
Type
Schools of Medicine
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Bossis, Ioannis; Roden, Richard B S; Gambhira, Ratish et al. (2005) Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol 79:6723-31
You, Jianxin; Croyle, Jennie L; Nishimura, Akiko et al. (2004) Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 117:349-60
Wells, Susanne I; Aronow, Bruce J; Wise, Trisha M et al. (2003) Transcriptome signature of irreversible senescence in human papillomavirus-positive cervical cancer cells. Proc Natl Acad Sci U S A 100:7093-8
Nishimura, A; Ono, T; Ishimoto, A et al. (2000) Mechanisms of human papillomavirus E2-mediated repression of viral oncogene expression and cervical cancer cell growth inhibition. J Virol 74:3752-60
Francis, D A; Schmid, S I; Howley, P M (2000) Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. J Virol 74:2679-86
Wells, S I; Francis, D A; Karpova, A Y et al. (2000) Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways. EMBO J 19:5762-71